Hypermarcas (OTCMKTS:HYPMY – Get Free Report) and Gyre Therapeutics (NASDAQ:GYRE – Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership.
Valuation & Earnings
This table compares Hypermarcas and Gyre Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Hypermarcas | $1.38 billion | 2.04 | $213.10 million | $0.50 | 8.00 |
| Gyre Therapeutics | $110.06 million | 4.29 | $5.03 million | ($0.20) | -21.15 |
Risk & Volatility
Hypermarcas has a beta of 0.78, suggesting that its share price is 22% less volatile than the S&P 500. Comparatively, Gyre Therapeutics has a beta of 2.14, suggesting that its share price is 114% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current recommendations and price targets for Hypermarcas and Gyre Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Hypermarcas | 0 | 1 | 0 | 1 | 3.00 |
| Gyre Therapeutics | 1 | 1 | 0 | 0 | 1.50 |
Profitability
This table compares Hypermarcas and Gyre Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Hypermarcas | 19.77% | 12.68% | 6.78% |
| Gyre Therapeutics | -14.80% | -7.39% | -5.74% |
Institutional and Insider Ownership
24.0% of Gyre Therapeutics shares are owned by institutional investors. 9.5% of Gyre Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Summary
Hypermarcas beats Gyre Therapeutics on 9 of the 13 factors compared between the two stocks.
About Hypermarcas
Hypermarcas was a Brazilian consumer-products and pharmaceutical company that later adopted the name Hypera Pharma. The company refocused its operations on pharmaceuticals after divesting a number of businesses in other consumer-goods categories. Today, Hypera Pharma develops, manufactures and markets medicines in Brazil, including prescription drugs, over-the-counter products and branded generics. Its portfolio also includes vitamins and supplements, and it sells products under brands such as Neo Química and Mantecorp.
About Gyre Therapeutics
Gyre Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for liver and other chronic diseases. The company operates in the United States and China, including through its China-based subsidiary, Beijing Continent Pharmaceuticals. Its pipeline includes hydronidone, also known as F351, an oral drug candidate being developed for liver fibrosis associated with chronic hepatitis B. Gyre is also developing treatments for other serious conditions, including acute-on-chronic liver failure.
Receive News & Ratings for Hypermarcas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hypermarcas and related companies with MarketBeat.com's FREE daily email newsletter.
